EP0087374B1 - Allantoin-hydrolyzed animal protein product - Google Patents
Allantoin-hydrolyzed animal protein product Download PDFInfo
- Publication number
- EP0087374B1 EP0087374B1 EP19830400376 EP83400376A EP0087374B1 EP 0087374 B1 EP0087374 B1 EP 0087374B1 EP 19830400376 EP19830400376 EP 19830400376 EP 83400376 A EP83400376 A EP 83400376A EP 0087374 B1 EP0087374 B1 EP 0087374B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- allantoin
- weight
- skin preparation
- animal protein
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 235000021120 animal protein Nutrition 0.000 title claims description 26
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 74
- 229960000458 allantoin Drugs 0.000 claims description 37
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 25
- 102000008186 Collagen Human genes 0.000 claims description 21
- 108010035532 Collagen Proteins 0.000 claims description 21
- 229920001436 collagen Polymers 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000003205 fragrance Substances 0.000 claims description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 8
- 239000006210 lotion Substances 0.000 claims description 8
- -1 skin toner Substances 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 5
- 239000004202 carbamide Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 4
- 229940091173 hydantoin Drugs 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- FQCSIUSICFAMDD-UHFFFAOYSA-N 2-oxopyrrolidine-1-carboxylic acid;sodium Chemical compound [Na].OC(=O)N1CCCC1=O FQCSIUSICFAMDD-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 claims description 3
- 229940101267 panthenol Drugs 0.000 claims description 3
- 239000011619 pantothenol Substances 0.000 claims description 3
- 235000020957 pantothenol Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 description 7
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Chemical class 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001875 compounds Chemical group 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 229920002114 octoxynol-9 Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- DMVGDAWWCIUOJI-FJXQXJEOSA-N (2R)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide (2,5-dioxoimidazolidin-4-yl)urea Chemical compound NC(=O)NC1NC(=O)NC1=O.CC(C)(CO)[C@@H](O)C(=O)NCCCO DMVGDAWWCIUOJI-FJXQXJEOSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/002—Aftershave preparations
Definitions
- the present invention relates to a stable form of allantoin which may be used in various skin preparations and other products in amounts of at least 0.5% by weight allantoin, without the allantoin crystallizing out of solution.
- Allantoin glycol diureide
- derivatives thereof such as Alpantha (Schuylkill Chemical Co., Philadelphia, Pa. trademark for "Allantoin DL-Panthenol Modified"
- Allantoin DL-Panthenol Modified are known for their soothing, skin softening and healing activity and have been used in 0.2% concentrations in creams, lotions, lipsticks, hair products (anti-dandruff), cosmetic gels (for their anti-irritant properties), cleansers (removal of scaly and calloused tissue), and moisturizers (increase water-binding capacity of the tissues).
- a complex or otherwise combined mixture of allantoin and hydrolyzed collagen-derived animal protein which affords allantoin in a form which is easily solubilized in aqueous-alcoholic solutions in amounts of from 0.05% up to 5% and preferably from 0.5 to 2% based on the weight of allantoin.
- solutions may take the form of stable soothing hydroalcoholic skin preparations, such as colognes, after-shave lotions, skin toners, after bath splash and the like.
- the allantoin in the form of its complex or otherwise combined state, such as hydrogen bonding, with the hydrolyzed collagen-derived animal protein will remain fully dissolved in the solution, without forming crystals, over extended periods of time.
- the complex or otherwise combined allantoin and hydrolyzed collagen-derived animal protein product of the invention will contain the hydrolyzed collagen-derived animal protein in a weight ratio to the allantoin of within the range of from 100:1 to 1:1, preferably from 5:1 to 1:1, and optimally 1:1.
- the method for preparing the complex of the invention includes the steps of mixing allantoin and hydrolyzed collagen-derived animal protein in aqueous medium at a temperature of from about 45 to about 80°C, preferably from about 55 to about 75°C and more preferably from about 60 to about 65°C, for a period of from a few minutes (for example, 10 to 15 minutes) up to 1-1/2 hours or more to form a clear aqueous solution containing the complex.
- the clear aqueous solution will contain from 0.05 to 5% and preferably from 0.5 to 2% allantoin, and from 0.1 to 10% and preferably from 0.1 to 1.5% hydrolyzed collagen-derived animal protein.
- the clear solution comprising the product of the invention may be used as such in the formation of any of the skin preparations mentioned or other products.
- the clear solution containing the complex of the invention may be dried, for example, freeze dried (or lyophilized) to form the complex or otherwise combined allantoin-hydrolyzed collagen-derived animal protein product in the form of a dry powder which may be subsequently added to water to form a solution or just simply added as a solid to powders, such as body and foot powders, emulsions, shampoos, acne products and the like.
- the hydrolyzed collagen-derived animal protein has a molecular weight of within the range of from 100 to 200,000 and containing various amino acids including glycine, alanine, serine, threonine, proline, hydroxyproline, valine, isoleucine, phenylalanine, tyrosine, cystine/cysteine, methionine, aspartic acid, glutamic acid, arginine, histidine, lysine and hydroxylysine.
- various amino acids including glycine, alanine, serine, threonine, proline, hydroxyproline, valine, isoleucine, phenylalanine, tyrosine, cystine/cysteine, methionine, aspartic acid, glutamic acid, arginine, histidine, lysine and hydroxylysine.
- collagen hydrolysates and derivatives referred to by the trademark Croteins manufactured by Croda, Inc., N.Y.C., Umordant sold by Pentapharm, Inc., Super-Pro 100 sold by Stepan Chemical Co., Proto-Lan 20 sold by Maybrook Inc., Lexein X-250 sold by Inolex Corp., Lanasan CL sold by Sandoz, Inc. and Peptein 2000 sold by Hormel.
- the Croda product is formed by hydrolyzing collagen (by alkali, acid or enzyme hydrolysis) and breaking the long collagen chains so that the molecular weight is reduced from the millions to hydrocolloids ranging from a molecular weight of 100 to 300,000 and preferably from 100 to 200,000.
- Amino acid composition of preferred collagen derived protein is set out below.
- the combined allantoin-hydrolyzed collagen-derived animal protein product of the invention may be employed in a wide variety of products.
- a preferred product is a stable skin preparation which contains from 0.5 to 15% and preferably from 0.5 to 7% by weight of the complex or combined allantoin-hydrolyzed collagen-derived animal protein product.
- the stable skin preparation also contains panthenol, which serves as a skin moisturizer and humectant and is converted to an essential vitamin B-5 for the normal growth and toning of the tissue, present in an amount within the range of from 0.1 to 10% by weight, and preferably from 0.1 to 3% by weight; and urea, which functions as a skin conditioner, water-binding agent or skin softener present in an amount within the range of from 0.1 to 10%, and preferably from 0.1 to 5% by weight.
- panthenol which serves as a skin moisturizer and humectant and is converted to an essential vitamin B-5 for the normal growth and toning of the tissue, present in an amount within the range of from 0.1 to 10% by weight, and preferably from 0.1 to 3% by weight
- urea which functions as a skin conditioner, water-binding agent or skin softener present in an amount within the range of from 0.1 to 10%, and preferably from 0.1 to 5% by weight.
- the above skin preparation will be in the form of an aqueous-alcoholic solution and as such will contain ethanol or isopropyl alcohol in an amount within the range of from 2.5 to 70%, and preferably from 10 to 30% by weight, and water in an amount within the range of from 20 to 80%, and preferably from 40 to 75% by weight.
- the aqueous-alcoholic solution will contain a weight ratio of water to alcohol of within the range of from 9:1 to 1:1, and preferably from 4:1 to 1:1.
- the hydroalcoholic skin preparation of the invention may contain amounts of allantoin (greater than 0.5%) heretofore never retained in solution for extended periods of time. This apparently has been achieved by employing the allantoin in combined form with the hydrolyzed animal protein. It is theorized that the allantoin forms a complex with hydrolyzed animal protein which complex is substantially more soluble in the hydroalcoholic solution than is the allantoin by itself and so remains in solution for indeterminate periods. The result is that large amounts of allantoin (greater than 0.5%) may be employed to provide even more skin soothing preparations which remain stable over extended periods of time without having the allantoin crystallize out.
- the stable soothing skin preparation containing the combined allantoin-hydrolyzed animal protein product may also comprise colognes, after-shave lotions, skin toners, emulsions, powders and the like.
- skin preparations may include preservatives, examples of which include dimethyldimethoyl hydantoin, benzyl alcohol, imidazolidinyl urea, parabens and the like usually employed in amounts within the range of from 0.05 to 1.25% by weight, humectants, such as, sodium 2-pyrrolidone carboxylic acid, sorbitol, polyethylene glycols, propylene glycol, glycerine or other known humectants usually employed in amounts within the range of from 0.1 to 20% by weight, fragrances in amounts within the range of from 0 to 35%, and preferably from 0.1 to 20% by weight depending upon the ultimate use of the skin preparation; and solubilizing agents and emulsifiers for the fragrances, such as poly
- the skin preparation may also include therapeutic agents, such as benzoyl peroxide, methyl salicylate or sun-screens in amounts normally employed for the particular therapeutic agent present.
- therapeutic agents such as benzoyl peroxide, methyl salicylate or sun-screens in amounts normally employed for the particular therapeutic agent present.
- Preferred formulations within the scope of the present invention contain from 0.6 to 3.5% by weight combined allantoin-collagen-derived animal protein, from 0.1 to 3% by weight d- or dl-panthenol, from 0.1 to 5% by weight urea, preservatives, such as benzyl alcohol, imidazolidinyl urea and/or dimethyldimethoyl hydantoin, humectants such as sodium-2-pyrrolidone carboxylic acid, emulsifiers, such as polyoxyethylene octyl phenyl ether, feel enhancers, such as polyoxyethylene glycerine, fragrance, water and ethanol or isopropyl alcohol.
- preservatives such as benzyl alcohol, imidazolidinyl urea and/or dimethyldimethoyl hydantoin
- humectants such as sodium-2-pyrrolidone carboxylic acid
- the skin preparations containing the combined allantoin-hydrolyzed animal protein product may be prepared as follows.
- Ethanol or isopropyl alcohol and where present, preservatives such as benzyl alcohol, fragrance oils, and emulsifiers and solubilizing agents for the fragrance oils are mixed together to form a first mixture.
- Allantoin, hydrolyzed animal protein, d- or dl-panthenol, urea, and, where present, humectants, preservatives such as dimethyldimethoyl hydantoin and water are mixed together to form a second mixture containing the allantoin-hydrolyzed animal protein combined product.
- the second mixture is heated to about 60 to 65°C or until clear, and then cooled to about 25°C.
- the second mixture is added to the first mixture with agitation and the mixture is allowed to age for 2 to 4 days.
- the mixture is then chilled at 0 to 4°C, filtered and coloring solution is added to form the skin preparation of the invention.
- a combined allantoin-hydrolyzed animal protein product in accordance with the invention was prepared as described below.
- 0.5 Grams allantoin and 0.5 gm hydrolyzed collagen-derived animal protein are mixed with 66 gm of water and the mixture was heated at 60 to 65°C for about 10 minutes until a clear solution forms. The mixture is then allowed to cool to room temperature and is then ready for use as an additive in colognes, after-shave lotions, skin toners, shampoos, acne products, emulsions, and the like.
- the above solution may be freeze-dried to form a concentrate or powder comprising the combined allantoin-hydrolyzed collagen-animal protein which may be used in powder compositions such as body and foot powders, various cosmetics, and the like.
- a stable soothing cologne having the following composition was prepared as described below.
- the ingredients identified by Mix A were mixed together to form a first mixture.
- the ingredients identified by Mix B were mixed together to form a second mixture which was heated to 60-65°C until a clear solution formed and then cooled to room temperature.
- the first mixture was then added to the second mixture (containing the combined allantoin-hydrolyzed animal protein product) with stirring and the combined mixture was then chilled to Q-4°C, and filtered through a #7 Ertel pad.
- the color solution was then added to form the soothing cologne of the invention wherein the allantoin remained stable and in solution, without crystallizing out, over extended periods of several months.
- a stable soothing after-shave lotion having the following composition was prepared as described in Example 1.
- the after-shave lotion produced as described above was found to have excellent stability with the allantoin remaining in solution, without crystallizing out, over extended periods of time.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
- The present invention relates to a stable form of allantoin which may be used in various skin preparations and other products in amounts of at least 0.5% by weight allantoin, without the allantoin crystallizing out of solution.
- Allantoin (glyoxyl diureide) and derivatives thereof such as Alpantha (Schuylkill Chemical Co., Philadelphia, Pa. trademark for "Allantoin DL-Panthenol Modified") are known for their soothing, skin softening and healing activity and have been used in 0.2% concentrations in creams, lotions, lipsticks, hair products (anti-dandruff), cosmetic gels (for their anti-irritant properties), cleansers (removal of scaly and calloused tissue), and moisturizers (increase water-binding capacity of the tissues).
- From US-A-3 941 722 it is known that allantoine being an amphoteric compound forms "addition compounds" with various substances, e.g. with proteins. In this document a composition is disclosed comprising essentially three components, namely allantoin, a usual collagen protein and Crotein (a hydrolyzed collagen protein) which composition is readily soluble in water and is employed for skin treatments.
- Until now, notwithstanding the acknowledged therapeutic qualities of allantoin and its derivatives including allantoin dl-panthenol modified, the amount of allantoin or allantoin equivalent contained in these compositions and employed in hydroalcoholic solutions (also referred to as aqueous-alcoholic solutions), such as after-shave lotions and colognes, has been severely restricted to relatively small amounts of 0.2% by weight or less. This is because when amounts of allantoin or allantoin dl-panthenol modified of greater than 0.25% by weight (based on the amount of allantoin) are employed in such hydroalcoholic solutions, the allantoin tends to crystallize out of solution within a relatively short period of time.
- Accordingly, a long felt need exists in the market place for a stable form of allantoin which may be used in solution in amounts greater than 0.25% (based on the weight of allantoin) and upwards of 0.5% and more without crystallizing out of solution.
- In accordance with the present invention, a complex or otherwise combined mixture of allantoin and hydrolyzed collagen-derived animal protein is provided which affords allantoin in a form which is easily solubilized in aqueous-alcoholic solutions in amounts of from 0.05% up to 5% and preferably from 0.5 to 2% based on the weight of allantoin. Such solutions may take the form of stable soothing hydroalcoholic skin preparations, such as colognes, after-shave lotions, skin toners, after bath splash and the like. The allantoin in the form of its complex or otherwise combined state, such as hydrogen bonding, with the hydrolyzed collagen-derived animal protein, will remain fully dissolved in the solution, without forming crystals, over extended periods of time.
- The complex or otherwise combined allantoin and hydrolyzed collagen-derived animal protein product of the invention will contain the hydrolyzed collagen-derived animal protein in a weight ratio to the allantoin of within the range of from 100:1 to 1:1, preferably from 5:1 to 1:1, and optimally 1:1.
- The method for preparing the complex of the invention, includes the steps of mixing allantoin and hydrolyzed collagen-derived animal protein in aqueous medium at a temperature of from about 45 to about 80°C, preferably from about 55 to about 75°C and more preferably from about 60 to about 65°C, for a period of from a few minutes (for example, 10 to 15 minutes) up to 1-1/2 hours or more to form a clear aqueous solution containing the complex. The clear aqueous solution will contain from 0.05 to 5% and preferably from 0.5 to 2% allantoin, and from 0.1 to 10% and preferably from 0.1 to 1.5% hydrolyzed collagen-derived animal protein.
- The clear solution comprising the product of the invention may be used as such in the formation of any of the skin preparations mentioned or other products. If desired, the clear solution containing the complex of the invention may be dried, for example, freeze dried (or lyophilized) to form the complex or otherwise combined allantoin-hydrolyzed collagen-derived animal protein product in the form of a dry powder which may be subsequently added to water to form a solution or just simply added as a solid to powders, such as body and foot powders, emulsions, shampoos, acne products and the like.
- The hydrolyzed collagen-derived animal protein has a molecular weight of within the range of from 100 to 200,000 and containing various amino acids including glycine, alanine, serine, threonine, proline, hydroxyproline, valine, isoleucine, phenylalanine, tyrosine, cystine/cysteine, methionine, aspartic acid, glutamic acid, arginine, histidine, lysine and hydroxylysine. Among the preferred hydrolyzed animal protein materials suitable for use herein are the collagen hydrolysates and derivatives referred to by the trademark Croteins manufactured by Croda, Inc., N.Y.C., Umordant sold by Pentapharm, Inc., Super-Pro 100 sold by Stepan Chemical Co., Proto-Lan 20 sold by Maybrook Inc., Lexein X-250 sold by Inolex Corp., Lanasan CL sold by Sandoz, Inc. and Peptein 2000 sold by Hormel. The Croda product is formed by hydrolyzing collagen (by alkali, acid or enzyme hydrolysis) and breaking the long collagen chains so that the molecular weight is reduced from the millions to hydrocolloids ranging from a molecular weight of 100 to 300,000 and preferably from 100 to 200,000. Amino acid composition of preferred collagen derived protein is set out below.
- As indicated, the combined allantoin-hydrolyzed collagen-derived animal protein product of the invention may be employed in a wide variety of products. A preferred product is a stable skin preparation which contains from 0.5 to 15% and preferably from 0.5 to 7% by weight of the complex or combined allantoin-hydrolyzed collagen-derived animal protein product. The stable skin preparation also contains panthenol, which serves as a skin moisturizer and humectant and is converted to an essential vitamin B-5 for the normal growth and toning of the tissue, present in an amount within the range of from 0.1 to 10% by weight, and preferably from 0.1 to 3% by weight; and urea, which functions as a skin conditioner, water-binding agent or skin softener present in an amount within the range of from 0.1 to 10%, and preferably from 0.1 to 5% by weight.
- The above skin preparation will be in the form of an aqueous-alcoholic solution and as such will contain ethanol or isopropyl alcohol in an amount within the range of from 2.5 to 70%, and preferably from 10 to 30% by weight, and water in an amount within the range of from 20 to 80%, and preferably from 40 to 75% by weight. Thus, the aqueous-alcoholic solution will contain a weight ratio of water to alcohol of within the range of from 9:1 to 1:1, and preferably from 4:1 to 1:1.
- The hydroalcoholic skin preparation of the invention may contain amounts of allantoin (greater than 0.5%) heretofore never retained in solution for extended periods of time. This apparently has been achieved by employing the allantoin in combined form with the hydrolyzed animal protein. It is theorized that the allantoin forms a complex with hydrolyzed animal protein which complex is substantially more soluble in the hydroalcoholic solution than is the allantoin by itself and so remains in solution for indeterminate periods. The result is that large amounts of allantoin (greater than 0.5%) may be employed to provide even more skin soothing preparations which remain stable over extended periods of time without having the allantoin crystallize out.
- The stable soothing skin preparation containing the combined allantoin-hydrolyzed animal protein product may also comprise colognes, after-shave lotions, skin toners, emulsions, powders and the like. Accordingly, such skin preparations may include preservatives, examples of which include dimethyldimethoyl hydantoin, benzyl alcohol, imidazolidinyl urea, parabens and the like usually employed in amounts within the range of from 0.05 to 1.25% by weight, humectants, such as, sodium 2-pyrrolidone carboxylic acid, sorbitol, polyethylene glycols, propylene glycol, glycerine or other known humectants usually employed in amounts within the range of from 0.1 to 20% by weight, fragrances in amounts within the range of from 0 to 35%, and preferably from 0.1 to 20% by weight depending upon the ultimate use of the skin preparation; and solubilizing agents and emulsifiers for the fragrances, such as polyoxyethylene octyl phenyl ether and polyoxyethylene glycerine and other skin softeners, such as esters, lanolin, lanolin derivatives thereof and/or other conventional skin softeners, present in an amount within the range of from 0.1 to 10% by weight, and color as deemed necessary.
- The skin preparation may also include therapeutic agents, such as benzoyl peroxide, methyl salicylate or sun-screens in amounts normally employed for the particular therapeutic agent present.
- Preferred formulations within the scope of the present invention contain from 0.6 to 3.5% by weight combined allantoin-collagen-derived animal protein, from 0.1 to 3% by weight d- or dl-panthenol, from 0.1 to 5% by weight urea, preservatives, such as benzyl alcohol, imidazolidinyl urea and/or dimethyldimethoyl hydantoin, humectants such as sodium-2-pyrrolidone carboxylic acid, emulsifiers, such as polyoxyethylene octyl phenyl ether, feel enhancers, such as polyoxyethylene glycerine, fragrance, water and ethanol or isopropyl alcohol.
- The skin preparations containing the combined allantoin-hydrolyzed animal protein product may be prepared as follows.
- Ethanol or isopropyl alcohol, and where present, preservatives such as benzyl alcohol, fragrance oils, and emulsifiers and solubilizing agents for the fragrance oils are mixed together to form a first mixture.
- Allantoin, hydrolyzed animal protein, d- or dl-panthenol, urea, and, where present, humectants, preservatives such as dimethyldimethoyl hydantoin and water are mixed together to form a second mixture containing the allantoin-hydrolyzed animal protein combined product. The second mixture is heated to about 60 to 65°C or until clear, and then cooled to about 25°C.
- The second mixture is added to the first mixture with agitation and the mixture is allowed to age for 2 to 4 days. The mixture is then chilled at 0 to 4°C, filtered and coloring solution is added to form the skin preparation of the invention.
- The following Examples represent preferred embodiments of the invention.
- A combined allantoin-hydrolyzed animal protein product in accordance with the invention was prepared as described below.
- 0.5 Grams allantoin and 0.5 gm hydrolyzed collagen-derived animal protein (Crotein@ SPA) are mixed with 66 gm of water and the mixture was heated at 60 to 65°C for about 10 minutes until a clear solution forms. The mixture is then allowed to cool to room temperature and is then ready for use as an additive in colognes, after-shave lotions, skin toners, shampoos, acne products, emulsions, and the like.
- If desired, the above solution may be freeze-dried to form a concentrate or powder comprising the combined allantoin-hydrolyzed collagen-animal protein which may be used in powder compositions such as body and foot powders, various cosmetics, and the like.
-
- The ingredients identified by Mix A were mixed together to form a first mixture. The ingredients identified by Mix B were mixed together to form a second mixture which was heated to 60-65°C until a clear solution formed and then cooled to room temperature. The first mixture was then added to the second mixture (containing the combined allantoin-hydrolyzed animal protein product) with stirring and the combined mixture was then chilled to Q-4°C, and filtered through a #7 Ertel pad. The color solution was then added to form the soothing cologne of the invention wherein the allantoin remained stable and in solution, without crystallizing out, over extended periods of several months.
-
- The after-shave lotion produced as described above was found to have excellent stability with the allantoin remaining in solution, without crystallizing out, over extended periods of time.
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT83400376T ATE27397T1 (en) | 1982-02-24 | 1983-02-23 | PRODUCT OF ALLANTOIN AND HYDROLYZED ANIMAL PROTEINS. |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35172282A | 1982-02-24 | 1982-02-24 | |
US383404 | 1982-06-01 | ||
US06/383,404 US4374766A (en) | 1982-06-01 | 1982-06-01 | Combined allantoin-hydrolyzed animal protein product and method |
US06/449,117 US4416873A (en) | 1982-06-01 | 1982-12-13 | Combined allantoin-hydrolyzed animal protein skin preparation |
US449117 | 1982-12-13 | ||
US351722 | 2003-01-27 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0087374A2 EP0087374A2 (en) | 1983-08-31 |
EP0087374A3 EP0087374A3 (en) | 1984-05-16 |
EP0087374B1 true EP0087374B1 (en) | 1987-05-27 |
Family
ID=27408014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19830400376 Expired EP0087374B1 (en) | 1982-02-24 | 1983-02-23 | Allantoin-hydrolyzed animal protein product |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0087374B1 (en) |
AU (1) | AU562620B2 (en) |
CA (1) | CA1224209A (en) |
DE (1) | DE3371738D1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1470824A1 (en) * | 2002-12-10 | 2004-10-27 | L-MAbs B.V. | Affinity proteins for controlled application of cosmetic substances |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3941722A (en) * | 1974-05-06 | 1976-03-02 | Chattem Drug & Chemical Company | Bath beads containing allantoin |
CA1187486A (en) * | 1981-07-27 | 1985-05-21 | Sebastian B. Mecca | Allantoin collagen amino acid compositions |
-
1983
- 1983-02-10 AU AU11312/83A patent/AU562620B2/en not_active Ceased
- 1983-02-18 CA CA000421952A patent/CA1224209A/en not_active Expired
- 1983-02-23 DE DE8383400376T patent/DE3371738D1/en not_active Expired
- 1983-02-23 EP EP19830400376 patent/EP0087374B1/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
DE3371738D1 (en) | 1987-07-02 |
AU562620B2 (en) | 1987-06-18 |
EP0087374A3 (en) | 1984-05-16 |
EP0087374A2 (en) | 1983-08-31 |
AU1131283A (en) | 1983-09-01 |
CA1224209A (en) | 1987-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4416873A (en) | Combined allantoin-hydrolyzed animal protein skin preparation | |
JP3803030B2 (en) | Topical composition containing whey protein | |
US5458881A (en) | N-acylated derivatives of mixtures of amino acids derived from hydrolysates of cereal proteins and their applications | |
JP3157823B2 (en) | Water-containing paste-type pharmaceutical composition | |
US4839164A (en) | Trehalose containing cosmetic composition and method of using it | |
US5153230A (en) | Topical skin cream composition | |
US4374766A (en) | Combined allantoin-hydrolyzed animal protein product and method | |
JP2000327552A (en) | Skin preparation for external use | |
JP3497932B2 (en) | How to prevent odor and discoloration of water-containing cosmetics | |
EP0533408A2 (en) | Cosmetics and pharmaceuticals containing extensins | |
EP0087374B1 (en) | Allantoin-hydrolyzed animal protein product | |
US6977081B1 (en) | Facial cream composition containing allantoin | |
JP3272743B2 (en) | Placenta or liver extract having stable SOD activity and external preparation composition containing the same | |
EP0344708B1 (en) | Composition for external application to skin | |
JPH0892062A (en) | External preparation | |
JPH08198741A (en) | Biological hyarulonic acid synthesis promoter | |
JP2011046690A (en) | Composition for hair-restoring and growing agent | |
JPH09176030A (en) | Medicine for stimulating secretion of sebum | |
US20220362348A1 (en) | Lactoferrin, derived peptide thereof and method thereof for inhibiting and/or alleviating lipid synthesis | |
JPH1077209A (en) | Cosmetic and its production | |
JP3434635B2 (en) | How to prevent odor and discoloration of water-containing cosmetics | |
JPH0570333A (en) | Skin medicine for external use | |
JPH05339140A (en) | Skin cosmetic | |
US20230002449A1 (en) | Derived peptide of lactoferrin and method thereof for promoting and/or increasing lipid synthesis | |
JP2006028020A (en) | Cosmetic composition comprising collagen and raw sugar extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19841016 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19870527 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 19870527 Ref country code: BE Effective date: 19870527 Ref country code: AT Effective date: 19870527 |
|
REF | Corresponds to: |
Ref document number: 27397 Country of ref document: AT Date of ref document: 19870615 Kind code of ref document: T |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19870531 |
|
REF | Corresponds to: |
Ref document number: 3371738 Country of ref document: DE Date of ref document: 19870702 |
|
ET | Fr: translation filed | ||
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19880229 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19930126 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19930222 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19930304 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19930429 Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19940223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19940228 Ref country code: CH Effective date: 19940228 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19940223 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19941031 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19941101 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: AUV Free format text: LE BREVET CI-DESSUS EST TOMBE EN DECHEANCE, FAUTE DE PAIEMENT, DE LA 12E ANNUITE. |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |